PIK3CA was found to be mutated in 7% of cases and PTEN mutations were also found in 7% while mutation was not detected in LPAR4. To assess whether these relatively frequent mutations have any prognostic value, we performed survival analysis in the genes of GPCR-mediated PI3K pathway in aggressive thyroid cancer (PDTC and ATC). This evidence concerns the gene LPAR4 and thyroid cancer.